Cancer Genetics (CGIX) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year Revenue Growth and Highlights Path to Future Profitability
November 10, 2016 7:00 AM EST
Company reports third quarter revenues of $6.8 Million, an increase of 68% over the third quarter of 2015The revenue growth rate was 58% for the first 9 months of 2016 as compared to 2015Company continues to decrease operating expenses both in sequential quarters and year over yearSigned contracts for expected future revenue with pharmaceutical and biotech companies have increased to $49 MillionCancer Genetics will host a conference call Thursday, November 10, 2016 at 8:30 AM Eastern Time (ET) / 5:30 AM Pacific Time (PT)
... More
